



IFW

PATENT
ATTORNEY DOCKET NO. 00742/058004

Certificate of Mailing: Date of Deposit: August 4, 2004

I hereby certify under 37 C.F.R. § 1.8(a) that this correspondence is being deposited with the United States Postal Service as **first class mail** with sufficient postage on the date indicated above and is addressed to Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Alma Woodberry
Printed name of person mailing correspondence

Alma Woodberry
Signature of person mailing correspondence

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:	Junying Yuan et al.	Art Unit:	1626
Serial No.:	10/802,902	Examiner:	Not Yet Assigned
Filed:	March 16, 2004	Customer No.:	21559
Title:	SMALL MOLECULES USED TO INCREASE CELL DEATH		

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Applicants submit the references listed on the enclosed Form PTO-1449.

Submission of this statement is not a representation that a search has been made, nor is the inclusion of information in this statement an admission that the information is material to patentability.

Under 35 U.S.C. § 120, this application relies on the earlier filing date of application serial numbers 09/736,502, filed on December 13, 2000; and 10/196,080, filed on July 16, 2002. All of the references listed on the attached PTO 1449 were submitted to and/or cited by the Office in the prior applications and, therefore, copies of these

references are not provided for this application:

This statement is being filed before the receipt of a first Office action on the merits.

If there are any charges or any credits, please apply them to Deposit Account No. 03-2095.

Respectfully submitted,

Date:

August 4, 2004



Kristina Bieker-Brady, Ph.D., P.C.
Reg. No. 39,109

Clark & Elbing LLP
101 Federal Street
Boston, MA 02110
Telephone: 617-428-0200
Facsimile: 617-428-7045



Sheet 1 of 2

SUBSTITUTE FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE (MODIFIED) PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary) (37 C.F.R. § 1.98(b))				Attorney Docket No. 00742/058004 Serial No. 10/802,902 Applicant Junying Yuan et al. Filing Date March 16, 2004 Group 1626 IDS Filed August 4, 2004		
U.S. PATENTS						
Examiner's Initials	Patent Number	Issue Date	Patentee	Class	Subclass	Filing Date (If Appropriate)
	3,798,258	03/19/74	Patchett et al.			
	5,834,309	11/10/98	Thompson et al.			
	5,955,593	09/21/99	Korsmeyer			
FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION						
Examiner's Initials	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation (Yes/No)
OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)						
	Adams et al., "The Bcl-2 Protein Family: Arbiters of Cell Survival," <i>Science</i> (1998) 281:1322-1326.					
	Chittenden et al., "A Conserved Domain in Bak, Distinct From BH1 and BH2, Mediates Cell Death and Protein Binding Functions," <i>EMBO J.</i> (1995) 14:5589-5596.					
	Clarke et al., "A Recombinant <i>bcl-x_S</i> Adenovirus Selectively Induces Apoptosis in Cancer Cells but Not in Normal Bone Marrow Cells," <i>Proceedings of the National Academy of Sciences USA</i> (1995) 92:11024-11028.					
	Dandliker et al., "Equilibrium and Kinetic Inhibition Assays Based upon Fluorescence Polarization," <i>Methods in Enzymology</i> (1981) 74:3-28.					
	Gross et al., "BCL-2 Family Members and the Mitochondria in Apoptosis," <i>Genes & Development</i> (1999) 13:1899-1911.					
	Holinger et al., "Bak BH3 Peptides Antagonize Bcl-x _L Function and Induce Apoptosis through Cytochrome c-independent Activation of Caspases," <i>Journal of Biological Chemistry</i> (1999) 274:13298-13304.					
	Kelekar et al., "Bcl-2-Family Proteins: the Role of the BH3 Domain in Apoptosis," <i>Trends In Cell Biology</i> (1998) 8:324-330.					
EXAMINER			DATE CONSIDERED			
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.						

SUBSTITUTE FORM PTO-1449 (MODIFIED)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	Attorney Docket No.	00742/058004
		Serial No.	10/802,902
		Applicant	Junying Yuan et al.
		Filing Date	March 16, 2004
		Group	1626
		IDS Filed	August 4, 2004
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)			
(37 C.F.R. § 1.98(b))			
OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)			
	Mahajan et al., "Bcl-2 and Bax Interactions in Mitochondria Probed with Green Fluorescent Protein and Fluorescence Resonance Energy Transfer," <i>Nature Biotechnology</i> (1998) 16:547-552.		
	McDonnell et al., "Solution Structure of the Proapoptotic Molecule BID: A Structural Basis for Apoptotic Agonists and Antagonists," <i>Cell</i> (1999) 96:625-634.		
	Mikhailitsyn et al., <i>CA</i> (1992)116:235197.		
	Mikhailitsyn et al., "A Search for New Antiparasitic Agents. 6. Synthesis of Haloidbenzamides Containing Nitrogen-related Benzophenone or Diphenyl Sulfonic Substitute and Study of Their Acute Toxicity," <i>Meditsinskaya Parazitologiya i Parazitamy Bolezni</i> , (1991) 4:43-46.		
	An English translation of Mikhailitsyn et al., "Search for New Antiparasitic Agents. 6. Synthesis of Haloidbenzamides Containing Nitrogen-related Benzophenone or Diphenyl Sulfonic Substitute and Study of Their Acute Toxicity," <i>Meditsinskaya Parazitologiya i Parazitamy Bolezni</i> , (1991) 4:43-46.		
	Minn et al., "Recent Progress on the Regulation of Apoptosis by Bcl-2 Family Members," <i>Advances In Immunology</i> (1998) 70:245-279.		
	Sattler et al., "Structure of Bcl-x _L -Bak Peptide Complex: Recognition Between Regulators of Apoptosis," <i>Science</i> (1997) 275:983-986.		
	Taylor et al., "Induction of Endogenous Bcl-xS through the Control of Bcl-x Pre-mRNA Splicing by Antisense Oligonucleotides," <i>Nature Biotechnology</i> (1999) 17:1097-1100.		
EXAMINER	DATE CONSIDERED		
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.			